The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. Vasilakis-Scaramozza, C., Persson, R., Hagberg, K., & Jick, S. Journal of the European Academy of Dermatology and Venereology, 2020. abstract bibtex © 2020 European Academy of Dermatology and Venereology Background: Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. Objective: To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. Methods: We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. Results: Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6–12.5), 4.6 (2.8–7.1) and 4.6 (2.8–7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. Conclusions: Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.
@article{
title = {The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database},
type = {article},
year = {2020},
identifiers = {[object Object]},
id = {7b5609b6-4270-3eef-968b-d2f168f842dd},
created = {2020-03-13T14:20:51.698Z},
file_attached = {false},
profile_id = {55db6c4f-f403-3067-b2bc-e55c8dd5dd2b},
last_modified = {2020-03-13T14:20:51.698Z},
read = {false},
starred = {false},
authored = {true},
confirmed = {false},
hidden = {false},
private_publication = {false},
abstract = {© 2020 European Academy of Dermatology and Venereology Background: Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. Objective: To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. Methods: We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. Results: Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6–12.5), 4.6 (2.8–7.1) and 4.6 (2.8–7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. Conclusions: Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.},
bibtype = {article},
author = {Vasilakis-Scaramozza, C. and Persson, R. and Hagberg, K.W. and Jick, S.},
journal = {Journal of the European Academy of Dermatology and Venereology}
}
Downloads: 0
{"_id":"HGWy6eaX93sjP5dft","bibbaseid":"vasilakisscaramozza-persson-hagberg-jick-theriskoftreatedanxietyandtreateddepressionamongpatientswithpsoriasisandpsoriaticarthritistreatedwithapremilastcomparedtobiologicsdmardsandcorticosteroidsacohortstudyintheunitedstatesmarketscandatabase-2020","authorIDs":["8pQFytfrD3qaBJXkZ","dzrH2gg3b3qJekRnP"],"author_short":["Vasilakis-Scaramozza, C.","Persson, R.","Hagberg, K.","Jick, S."],"bibdata":{"title":"The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database","type":"article","year":"2020","identifiers":"[object Object]","id":"7b5609b6-4270-3eef-968b-d2f168f842dd","created":"2020-03-13T14:20:51.698Z","file_attached":false,"profile_id":"55db6c4f-f403-3067-b2bc-e55c8dd5dd2b","last_modified":"2020-03-13T14:20:51.698Z","read":false,"starred":false,"authored":"true","confirmed":false,"hidden":false,"private_publication":false,"abstract":"© 2020 European Academy of Dermatology and Venereology Background: Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. Objective: To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. Methods: We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. Results: Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6–12.5), 4.6 (2.8–7.1) and 4.6 (2.8–7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. Conclusions: Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.","bibtype":"article","author":"Vasilakis-Scaramozza, C. and Persson, R. and Hagberg, K.W. and Jick, S.","journal":"Journal of the European Academy of Dermatology and Venereology","bibtex":"@article{\n title = {The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database},\n type = {article},\n year = {2020},\n identifiers = {[object Object]},\n id = {7b5609b6-4270-3eef-968b-d2f168f842dd},\n created = {2020-03-13T14:20:51.698Z},\n file_attached = {false},\n profile_id = {55db6c4f-f403-3067-b2bc-e55c8dd5dd2b},\n last_modified = {2020-03-13T14:20:51.698Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {false},\n hidden = {false},\n private_publication = {false},\n abstract = {© 2020 European Academy of Dermatology and Venereology Background: Anxiety and depression are common among psoriasis and psoriatic arthritis (PsA) patients, but rates may differ by treatment. Objective: To quantify the risk of incident treated anxiety, depression and mixed anxiety + depression in users of apremilast compared with users of other treatments for psoriasis and PsA. Methods: We conducted two separate cohort studies of psoriasis and PsA patients treated with apremilast, tumour necrosis factor inhibitor biologics, interleukin-17, -23 or -12/23 inhibitor biologics, conventional DMARDs or systemic corticosteroids in the United States MarketScan database. Cohort entry was date of first study drug after 21 March 2014. We identified cases who had a depression and/or anxiety diagnosis with a prescription for antidepressant/antianxiety medication within 30 days of the diagnosis code. We calculated incidence rates (IRs) and incidence rate ratios with 95% confidence intervals (CIs) for treated anxiety, treated depression and treated anxiety + depression per 1000 patient-years (PY) among patients. Results: Among the psoriasis cohort, IRs for each outcome were similar between exposure categories and highest among users of systemic corticosteroids alone. IRs (95% CI) for apremilast alone were 9.2 (6.6–12.5), 4.6 (2.8–7.1) and 4.6 (2.8–7.1) per 1000 PY for treated anxiety, treated depression and treated anxiety + depression, respectively. In the PsA cohort, the rate of anxiety was highest among users of apremilast alone; rates of depression and anxiety + depression were similar for apremilast compared with other PsA treatments. IRs for each outcome were also high for users of corticosteroids in both the psoriasis and PsA cohorts. Conclusions: Among patients with psoriasis, users of apremilast had similar rates of anxiety and depression as users of other non-corticosteroid systemic psoriasis treatments. Among PsA patients, users of apremilast had similar rates of depression and anxiety + depression compared with users of other systemic non-corticosteroid PsA drugs; however, the rate of anxiety was slightly higher.},\n bibtype = {article},\n author = {Vasilakis-Scaramozza, C. and Persson, R. and Hagberg, K.W. and Jick, S.},\n journal = {Journal of the European Academy of Dermatology and Venereology}\n}","author_short":["Vasilakis-Scaramozza, C.","Persson, R.","Hagberg, K.","Jick, S."],"bibbaseid":"vasilakisscaramozza-persson-hagberg-jick-theriskoftreatedanxietyandtreateddepressionamongpatientswithpsoriasisandpsoriaticarthritistreatedwithapremilastcomparedtobiologicsdmardsandcorticosteroidsacohortstudyintheunitedstatesmarketscandatabase-2020","role":"author","urls":{},"downloads":0},"bibtype":"article","creationDate":"2020-06-12T13:58:04.312Z","downloads":0,"keywords":[],"search_terms":["risk","treated","anxiety","treated","depression","patients","psoriasis","psoriatic","arthritis","treated","apremilast","compared","biologics","dmards","corticosteroids","cohort","study","united","states","marketscan","database","vasilakis-scaramozza","persson","hagberg","jick"],"title":"The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database","year":2020}